Table 3.
Meta-analysis of the miR-196a2 C>T polymorphism associated with hepatocellular carcinoma.
| Comparisons | OR | 95% CI | P | P h |
|---|---|---|---|---|
| Overall | ||||
| T versus C | 0.891 | 0.815–0.974 | 0.011 | 0.012 |
| TT versus CC | 0.783 | 0.649–0.943 | 0.010 | 0.007 |
| CT versus CC | 0.831 | 0.714–0.967 | 0.017 | 0.025 |
| CT/TT versus CC | 0.817 | 0.703–0.949 | 0.008 | 0.012 |
| TT versus TC/CC | 0.907 | 0.807 | 1.020 | 0.094 |
| Asian | ||||
| T versus C | 0.910 | 0.837–0.990 | 0.029 | 0.036 |
| TT versus CC | 0.817 | 0.684–0.976 | 0.026 | 0.021 |
| CT versus CC | 0.838 | 0.712–0.98 | 0.033 | 0.017 |
| CT/TT versus CC | 0.833 | 0.712–0.974 | 0.022 | 0.012 |
| TT versus TC/CC | 0.935 | 0.846–1.032 | 0.181 | 0.270 |
P h: P value of Q test for heterogeneity test; OR odds: odds ratio; CI: confidence interval; random-effects model was used when P h≦0.10; otherwise, fix-effects model was used.